Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

Also called NCT02537470

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 191 participants (enrolled count) (from the registry)
Sponsor
  • Integrium Registry lists this organization as a collaborator
Registry
  • NCT NCT02537470
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02537470. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes
Acronym
BRID
Condition
Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Biphasic Remogliflozin Etabonate
Intervention (Other)
Placebo
Lead sponsor
BHV Pharma (class: industry)
Collaborator
Integrium (class: industry)

Record details

Record id
cardio:ct-nct02537470
Content hash
51f40b7e94fdc8fae9f46e363b5b579fe631ab2f5a538492f9b8efce335838e8